BridgeMD
Compares treatment options for Ruptured Aneurysm
Official title European, Multi-center, Exploratory Trial to Assess WEB Versus Other Endovascular Treatment in Ruptured Aneurysms.
ClinicalTrials.gov ID: NCT06511245
What this study is testing
- What it's testing
- Comparison of efficacy and safety between WEB and other endovascular techniques
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Main
- Patient is above 18 years of age at the time of consent
- Patient has an identified acutely ruptured intracranial aneurysm requiring endovascular treatment (for the purposes of this study an acutely ruptured...
- Aneurysm dome diameter must be ≤ 10mm and within the diameter (and parent vessel diameter, as appropriate) range treatable by commercially available...
- Aneurysm is located on the anterior communicating artery complex segment (ACom), internal carotid artery terminus (ICAt), anterior cerebral artery...
You likely can't join if
- Aneurysm to be treated is unsuitable for endovascular treatment with commercially available WEB devices and/or all other available endovascular...
- Patient presenting as target aneurysm a blister like or dissecting aneurysm
- Patient has more than one aneurysm requiring treatment within 30 days of completion of treatment of the target aneurysm
- Patient with multiple aneurysms in whom ruptured aneurysm cannot be identified
- Patient has pre-morbid mRS \> 2
See the full eligibility criteria
- Main
- Patient is above 18 years of age at the time of consent
- Patient has an identified acutely ruptured intracranial aneurysm requiring endovascular treatment (for the purposes of this study an acutely ruptured IA patient is defined as a patient with computed tomography (CT)...
- Aneurysm dome diameter must be ≤ 10mm and within the diameter (and parent vessel diameter, as appropriate) range treatable by commercially available WEB devices as well as at least one other alternative commercially...
- Aneurysm is located on the anterior communicating artery complex segment (ACom), internal carotid artery terminus (ICAt), anterior cerebral artery (ACA), middle cerebral artery (MCA), basilar apex, posterior...
- Patient must be neurologically stable with a Hunt \& Hess score of I to III
- Patient or patient's legally authorized representative (LAR) has provided written informed consent Main
- Aneurysm to be treated is unsuitable for endovascular treatment with commercially available WEB devices and/or all other available endovascular treatment techniques used per standard site practice
- Patient presenting as target aneurysm a blister like or dissecting aneurysm
- Patient has more than one aneurysm requiring treatment within 30 days of completion of treatment of the target aneurysm
- Patient with multiple aneurysms in whom ruptured aneurysm cannot be identified
- Patient has pre-morbid mRS \> 2
The study team makes the final eligibility decision.
Where it's taking place
- Reims, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Reims, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.